You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letters
Prescribing in a pandemic: best use of oseltamivir in paediatric intensive care
  1. A C Seale1,2,
  2. F S Toussaint1,
  3. A Finn1,2,
  4. J I Fraser1
  1. 1University Hospitals Bristol NHS Foundation Trust, Bristol, UK
  2. 2Bristol Children's Vaccine Centre, University of Bristol, Bristol, UK
  1. Correspondence to Dr Anna Seale, Paediatric Intensive Care Unit, Bristol Children's Hospital, Upper Maudlin Street, Bristol BS2 8BJ, UK; anna.seale{at}gmail.com

https://doi.org/10.1136/adc.2010.183806

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    During the first summer wave of the 2009 pandemic caused by H1N1 Swine-Origin Flu Virus (H1N1), in contrast to some other areas in the UK,1 there was only one H1N1-positive paediatric admission to Bristol Children's Hospital paediatric intensive care unit (PICU). Guidelines for the care of children admitted critically ill were published online by the Health Protection Agency (HPA) in the UK on 24 October 2009,2 advising that treatment should be started on clinical grounds, without waiting for results, in all children with fever and critical illness (defined in this study as needing PICU admission) since oseltamivir is most effective if given within 48 h …

    View Full Text

    Footnotes

    • Competing interests AF is chief and principal investigator in clinical trials funded by Roche, who manufacture Oseltamivir, and undertakes paid consultancy for Astra-Zeneca, who manufacture flu vaccine—all funds are paid to his employer.

    • Provenance and peer review Not commissioned; internally peer reviewed.